Loading…
📊 Analyst reports All ratings →
09-15Buy · ₩130,000iM Securities: Excessive Concerns Over Clinical Hold08-27BuyMeritz Securities: Opakalim: More than just a second product08-27Buy · ₩160,000SK Securities: Securing future growth engines through Opakalim acquisition08-06Buy · ₩140,000Meritz Securities: Earnings trending upward with easing competitive landscape07-23Buy · ₩130,000iM Securities: Nothing has changed
📑 Recent filings Filings Radar →
09.23★★ Signed ₩63.3bn pharmaceutical supply agreement with US subsidiary09.17★★★★★🟢 In-licensed new drug candidate for Parkinson's disease09.14★★★ Signed pharmaceutical supply agreement with subsidiary (internal transaction)09.10★★★★🔴 US FDA clinical hold notification for epilepsy drug candidate08.26★★★★🟢 In-licensed epilepsy drug candidate and platform technology08.26★★★★🟢 Asset acquisition for exclusive rights to new drug candidate and platform
RSI 14
ExploreAll top movers →
Today's top 5 gainers
1WisePlanet Company+285.8%2TN Entertainment+30.0%3Phionx+30.0%4HT Robotics+29.9%5Woorinet+29.9%
More on KOSPI News
🔥 Today's top moversForeign flowsDividendsIPO calendarWeekly picksFilings